On March 25, 2026, Onconetix, Inc. filed an amended Form 8-K/A with the SEC, detailing significant leadership changes within the company. The report highlights the appointment of David White as the new Chief Executive Officer, effective March 18, 2026. White brings over 30 years of executive experience, having held various senior roles in multiple organizations, including Chief Executive Officer and Chief Financial Officer positions. His extensive background in corporate governance and operational execution is expected to steer Onconetix towards a more strategic direction.

The filing also notes the resignation of Timothy Ramdeen from the Board of Directors, effective immediately, which was not due to any disagreements with the management. In addition, Sammy Dorf has been appointed to the Board and will also serve on the Audit Committee. Dorf's experience as an entrepreneur and investor in regulated industries is anticipated to add valuable insights to the Board's strategic discussions.

The report indicates that these changes are part of a broader strategy to enhance governance controls and operational execution within the company. The Compensation Committee has also made adjustments to the compensation of other executives, reducing the monthly salary of the Interim Chief Financial Officer and the Lead Independent Director, effective from the same date as White's appointment.

Overall, these leadership changes are viewed positively, as they are expected to bring fresh perspectives and drive the company towards achieving its strategic goals. The market may react favorably to this news, reflecting confidence in the new leadership team’s ability to navigate the company through its next phase of growth.



Press Release distribution
National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.